Company / Financials
Tarsus Pharmaceuticals, Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$451.4M
FY2025 · +146.7% YoY
Net Income
-$66.4M
FY2025 · +42.5% YoY
Profit Margin
-14.7%
FY2025 · net income / revenue
ROE
-19.3%
FY2025 · return on equity
Total Assets
$562.2M
FY2025
Total Debt
$72.4M
0.21x debt/equity
Equity
$343.4M
FY2025
ROA
-11.8%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$451.4M+146.7% YoYNet Income HistoryProfit after all expenses and taxes-$66.4M+42.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$71.0M+41.1% YoYSG&A Expense HistorySelling, general, and administrative expenses$427.3M+80.1% YoYR&D Expense HistoryResearch and development spending$64.3M+20.5% YoYInterest Expense HistoryCost of borrowing and debt obligations$8.9M+13.8% YoYIncome Tax HistoryTotal income tax expense$2.1MEPS (Basic) HistoryBasic earnings per share-$4.62-83.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$4.62-83.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding38.3M+12.1% YoY